Is there a place for prophylaxis with DOACs in Klippel-Trenaunay syndrome and other low-flow vascular malformations with intravascular coagulopathy and thromboembolic events?

Although Direct Oral AntiCoagulants (DOACs) are first choice treatment in venous thromboembolism (VTE), in rare conditions, such as vascular anomalies and especially low-flow vascular malformations (VM), where the increased risk of thromboembolic events (TEE) is becoming increasingly evident, prophylaxis with DOACs has not yet been implemented [1,2].